Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Gilead Sciences, Inc.NASDAQ: GILD

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income turns negative

Q2 FY2026 operating income was -$10.39B, compared with $2.47B a year earlier. Trailing-twelve-month operating income was -$1.49B. Over 3 fiscal years it compounded at +16.9% a year.

Context

  • Operating income amounted to 39.7% of revenue in FY2025, up 34.0 pp from a year earlier.
  • Operating income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 18 analysts of -$259M (-102.2%) for the fiscal year ending Dec 2026, a slowdown from the +604.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$10.39B-501.9% QoQ
Last fiscal yearDec 2025
$11.7B+604.0% YoY
LTMJun 2026
-$1.49B-118.5% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-520.1%+12.9%+533.0 pp
1 year+604.0%-102.2%-706.2 pp
3-year CAGR+16.9%+15.5%-1.3 pp
5-year CAGR+13.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
11.7B USD
Year-over-year change
+604.0%
4-year CAGR
+4.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How GILD compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -118.5% is the lowest of 10, against a peer median of +6.2%.
  • Operating income amounts to 4.9% of revenue for GILD, versus a peer median of 25.7%.
GILD Competitors
Operating Income for GILD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$39.61B USD+76.5%+50.8%49.7%
JNJJohnson & JohnsonLTM Sep 2026$25.53B USD+6.2%+6.8%25.7%
ABBVAbbVie Inc.LTM Sep 2026$23.46B USD+159.5%+3.5%35.5%
PFEPfizer Inc.LTM Jun 2026$17.02B USD+2.2%-23.0%26.7%
NVSNovartis AGLTM Jun 2026$16.99B USD+1.8%+29.0%30.5%
AZNAstraZeneca PLCLTM Sep 2026$14.71B USD+14.9%+54.1%23.7%
MRKMerck & Co., Inc.LTM Jun 2026$11.06B USD-48.3%+8.7%16.7%
SNYSanofiLTM Jun 2026€7.24B EUR-8.6%-1.9%14.8%
GSKGSK plcLTM Jun 2026£6.87B GBP+34.1%+9.0%20.7%
GILDGilead Sciences, Inc.LTM Jun 2026-$1.49B USD-118.5%+16.9%4.9%
Peer median (excluding GILD) —+6.2%+8.7%25.7%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.31B27.28B27.12B28.75B29.44B
Cost of Revenue6.6B5.66B6.5B6.25B6.23B
Gross Profit20.7B21.62B20.62B22.5B23.21B
Gross Margin75.8%79.3%76.0%78.3%78.8%
Research & Development4.6B4.98B5.72B5.91B5.8B
Selling, General & Admin5.25B5.67B6.09B6.09B5.71B
Operating Expenses10.79B14.29B13.01B20.84B11.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
EBITDA11.33B8.85B10.5B4.43B13.58B
EBITDA Margin41.5%32.4%38.7%15.4%46.1%
Operating Income9.92B7.33B7.61B1.66B11.7B
Operating Margin36.3%26.9%28.0%5.8%39.7%
Interest Income0106M376M281M349M
Interest Expense1B935M944M977M1.02B
Other Income / Expenses(1.64B)(1.52B)(746M)(972M)(1.91B)
Income Before Tax8.28B5.81B6.86B690M9.8B
Pre-Tax Margin30.3%21.3%25.3%2.4%33.3%
Income Tax Expense2.08B1.25B1.25B211M1.29B
Net Income6.23B4.59B5.67B480M8.51B
Net Margin22.8%16.8%20.9%1.7%28.9%
EPS (Basic)4.963.664.540.386.84
EPS (Diluted)4.933.644.500.386.78
Weighted Avg Shares1.26B1.26B1.25B1.25B1.24B
Weighted Avg Shares (Diluted)1.26B1.26B1.26B1.26B1.26B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.